BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 28191610)

  • 1. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
    Robertson L; Kesteven P; McCaslin JE
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants: a guide for daily practice.
    Fontana P; Robert-Ebadi H; Bounameaux H; Boehlen F; Righini M
    Swiss Med Wkly; 2016; 146():w14286. PubMed ID: 26964028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
    Imberti D; Mastroiacovo D
    Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
    Finks SW; Trujillo TC; Dobesh PP
    Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
    Goldenberg NA; Takemoto CM; Yee DL; Kittelson JM; Massicotte MP
    Blood; 2015 Dec; 126(24):2541-7. PubMed ID: 26500341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants: evidence and unresolved issues.
    Chan N; Sobieraj-Teague M; Eikelboom JW
    Lancet; 2020 Nov; 396(10264):1767-1776. PubMed ID: 33248499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.